Page last updated: 2024-10-20

urea and Multiple Myeloma

urea has been researched along with Multiple Myeloma in 51 studies

pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.

Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.

Research Excerpts

ExcerptRelevanceReference
"Proteasome inhibitors belong to an important class of anticancer agents and bortezomib (Velcade(®)) has been Food and Drug Administration-approved for the treatment of multiple myeloma (MM) and mantle cell lymphoma."7.78Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma. ( Bachmann, AS; Ibarra-Rivera, TR; Opoku-Ansah, J; Pirrung, MC, 2012)
"Proteasome inhibitors belong to an important class of anticancer agents and bortezomib (Velcade(®)) has been Food and Drug Administration-approved for the treatment of multiple myeloma (MM) and mantle cell lymphoma."3.78Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma. ( Bachmann, AS; Ibarra-Rivera, TR; Opoku-Ansah, J; Pirrung, MC, 2012)
"UNTREATED PATIENTS SUFFERING FROM MYELOMATOSIS WERE ALLOCATED AT RANDOM FOR TREATMENT BY THE DAILY ORAL ADMINISTRATION OF EITHER CYCLOPHOSPHAMIDE OR MELPHALAN: 141 received cyclophosphamide and 133 melphalan."2.64Myelomatosis: comparison of melphalan and cyclophosphamide therapy. ( , 1971)
"347 patients with multiple myeloma diagnosed in Sichuan people's Hospital from April 2019 to July 2021 were selected."1.72[Correlation between Serum Free Light Chain and Blood Routine Parameters in Patients with Multiple Myeloma]. ( He, Y; Jiang, N; Li, D; Wang, JQ; Wang, ZB; Zhang, J, 2022)
"This study aims in optimizing and predicting the in-vivo activity of AT9283 as a monotherapy and evaluating its combination with paclitaxel."1.42Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel. ( Moawad, EY, 2015)
"We evaluated the in vitro antimyeloma activity of AT9283 alone and in combination with lenalidomide and the in vivo efficacy by using a xenograft mouse model of human MM."1.37Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. ( Anderson, KC; Bandi, M; Chauhan, D; Cirstea, D; Gorgun, G; Hideshima, T; Hu, Y; Mahindra, A; Munshi, NC; Nelson, EA; Patel, K; Pozzi, S; Raje, N; Rodig, S; Santo, L; Squires, M; Unitt, C; Vallet, S, 2011)
"Renal failure (RF) in multiple myeloma (MM) is considered an ominous complication even though, when timely therapy is started in patients with minimal damage, a high percentage of cases can achieve a regression."1.30Assessment of renal function in patients with multiple myeloma: the role of urinary proteins. ( Bernasconi, C; Bosoni, T; Castagnola, C; Corso, A; Klersy, C; Lazzarino, M; Moratti, R; Pagnucco, G; Serricchio, G; Zappasodi, P, 1999)
"Twenty-four untreated patients with myelomatosis were studied in order to characterize their anaemia, using standard haematological and ferrokinetic techniques, together with measurements of circulating erythropoietin, erythropoietin sensitivity of marrow cultures and in vitro measurements of haem synthesis."1.26Anaemia in patients with myelomatosis. ( Cavill, I; Jacobs, A; Kaaba, S; May, A; Smith, S; Ting, WC; Whittaker, JA, 1982)
"However, in the patients with possible protein deficiency and normal renal function, an elevation of plasma ribonuclease is, in general, associated with a decrease in serum albumin, transferrin and cholinesterase."1.26An assessment of the clinical usefulness of plasma ribonuclease assays. ( Citrin, DL; Rowan, RM; Shenkin, A, 1976)
"In 15 out of 35 patients with myelomatosis histological examination showed intravascular fibrin within the glomeruli, and this was associated with proliferation of the mesangial complex in 12."1.25The kidney and intravascular coagulation in myelomatosis. ( Preston, FE; Ward, AM, 1974)

Research

Studies (51)

TimeframeStudies, this research(%)All Research%
pre-199036 (70.59)18.7374
1990's3 (5.88)18.2507
2000's1 (1.96)29.6817
2010's9 (17.65)24.3611
2020's2 (3.92)2.80

Authors

AuthorsStudies
Li, D3
Jiang, N1
Wang, JQ1
Wang, ZB1
He, Y2
Zhang, J4
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X5
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S3
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC3
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Martin, EB1
Williams, A1
Wooliver, C1
Heidel, RE1
Adams, S1
Dunlap, J1
Ramirez-Alvarado, M1
Blancas-Mejia, LM1
Lands, RH1
Kennel, SJ1
Wall, JS1
Liubarets, TF1
Minchenko, ZM1
Dmytrenko, OO1
Khomenko, VI1
Reznikova, LS1
Shlyahtichenko, TY1
Tovstogan, AO1
Silayev, YO1
Cirstea, D2
Hideshima, T2
Santo, L2
Eda, H1
Mishima, Y1
Nemani, N1
Hu, Y2
Mimura, N1
Cottini, F1
Gorgun, G2
Ohguchi, H1
Suzuki, R1
Loferer, H1
Munshi, NC2
Raje, N2
Moawad, EY1
Hay, AE1
Murugesan, A1
DiPasquale, AM1
Kouroukis, T1
Sandhu, I1
Kukreti, V1
Bahlis, NJ1
Lategan, J1
Reece, DE1
Lyons, JF1
Sederias, J1
Xu, H1
Powers, J1
Seymour, LK1
Reiman, T1
Bandi, M1
Nelson, EA1
Rodig, S1
Vallet, S1
Pozzi, S1
Patel, K1
Unitt, C1
Squires, M1
Chauhan, D1
Mahindra, A1
Pei, XY1
Dai, Y1
Youssefian, LE1
Bodie, WW1
Takabatake, Y1
Felthousen, J1
Almenara, JA1
Kramer, LB1
Dent, P1
Grant, S1
Opoku-Ansah, J1
Ibarra-Rivera, TR1
Pirrung, MC1
Bachmann, AS1
Landau, HJ1
McNeely, SC1
Nair, JS1
Comenzo, RL1
Asai, T1
Friedman, H1
Jhanwar, SC1
Nimer, SD1
Schwartz, GK1
SOLOMON, A1
FAHEY, JL1
DAVIS, P1
RAVAULT, PP1
RIFFAT, G1
VIALA, JJ1
JUVANON, J1
Oyeyinka, GO1
Ofei, V1
Maddy, SQ1
Duah, OA1
Akafo, SK1
Aquaye, JK1
Dosoo, DK1
Harris, DC1
Ibels, LS1
Ravich, RB1
Isbister, JP1
Wells, JV1
Buckman, R1
Cuzick, J2
Galton, DA1
Ting, WC1
Cavill, I1
Jacobs, A1
Kaaba, S1
May, A1
Smith, S1
Whittaker, JA2
Corso, A1
Serricchio, G1
Zappasodi, P1
Klersy, C1
Bosoni, T1
Moratti, R1
Castagnola, C1
Lazzarino, M1
Pagnucco, G1
Bernasconi, C1
Shenkin, A1
Citrin, DL1
Rowan, RM1
Hobbs, JR1
San Miguel, JF1
González, M1
Gascón, A1
Moro, MJ1
Hernández, JM1
Ortega, F1
Jiménez, R1
Guerras, L1
Romero, M1
Casanova, F1
Montera Garcia, JM1
Felin, J1
Artal, A1
González Barón, M1
López Pascual, J1
Fernández Rañada, JM1
Bladé, J1
Rozman, C1
Cervantes, F1
Reverter, JC1
Montserrat, E1
Cooper, EH1
MacLennan, IC1
Augener, W1
Grey, HM1
Morse, JH1
Sjöquist, J1
Vaughan, MH1
Luks, CI1
Connell, GE1
Hansson, UB1
Martin, NH1
Montgomery, PC1
Dorrington, KJ1
Rockey, JH1
Pruzanski, W1
Jancelewicz, Z1
Underdown, B1
Peto, R1
Ward, AM1
Preston, FE1
Schrohenloher, RE1
Mestecky, J1
Stanton, TH1
Ward, DJ1
Lea, DJ1
Tuddenham, EG1
Bradley, J1
Lilleyman, JS1
James, DR1
Powles, R1
Smith, C1
Kohn, J1
Hamilton Fairley, G1
Wang, AC1
Fudenberg, HH1
Goldrosen, MH1
Freedman, MH1
Buchwald, BM1
Marchalonis, JJ1
Cone, RE1
Santer, V1
Dawson, AA1
Ogston, D1
Wetter, O1
Pery, P1
Fougereau, M1
Alexanian, R1
Haut, A1
Khan, AU1
Lane, M1
McKelvey, EM1
Migliore, PJ1
Stuckey, WJ1
Wilson, HE1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma[NCT01145989]Phase 28 participants (Actual)Interventional2011-02-15Completed
A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcad[NCT00443235]Phase 3260 participants (Anticipated)Interventional2005-03-31Completed
A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747]Phase 3390 participants (Anticipated)Interventional2006-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for urea and Multiple Myeloma

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
The immunoglobulins: a review.
    Journal of clinical pathology, 1969, Volume: 22, Issue:2

    Topics: Alkaline Phosphatase; Bence Jones Protein; gamma-Globulins; Heavy Chain Disease; Humans; Immunoglobu

1969

Trials

8 trials available for urea and Multiple Myeloma

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:6

    Topics: Aurora Kinases; Benzimidazoles; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Protein Kinase

2016
Report on the second myelomatosis trial after five years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults.
    British journal of cancer, 1980, Volume: 42, Issue:6

    Topics: Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Hemo

1980
Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
    British journal of cancer, 1980, Volume: 42, Issue:6

    Topics: Aged; Anemia; Creatinine; Female; Follow-Up Studies; Hemoglobins; Humans; Leukocyte Count; Male; Mid

1980
Myeloma and leukaemia trials.
    Proceedings of the Royal Society of Medicine, 1972, Volume: 65, Issue:3

    Topics: Clinical Trials as Topic; Humans; Leukemia; Multiple Myeloma; Prognosis; Serum Albumin; Urea

1972
Report on the first myelomatosis trial. I. Analysis of presenting features of prognostic importance.
    British journal of haematology, 1973, Volume: 24, Issue:1

    Topics: Adult; Aged; Alkaline Phosphatase; Bence Jones Protein; Calcium; Cyclophosphamide; Female; Hemoglobi

1973
Myelomatosis: comparison of melphalan and cyclophosphamide therapy.
    British medical journal, 1971, Mar-20, Volume: 1, Issue:5750

    Topics: Clinical Trials as Topic; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prognosis; Time Fac

1971
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
    JAMA, 1969, Jun-02, Volume: 208, Issue:9

    Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Proteins; Humans; Immunoelectrophoresis; M

1969
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
    JAMA, 1969, Jun-02, Volume: 208, Issue:9

    Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Proteins; Humans; Immunoelectrophoresis; M

1969
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
    JAMA, 1969, Jun-02, Volume: 208, Issue:9

    Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Proteins; Humans; Immunoelectrophoresis; M

1969
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
    JAMA, 1969, Jun-02, Volume: 208, Issue:9

    Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Proteins; Humans; Immunoelectrophoresis; M

1969

Other Studies

42 other studies available for urea and Multiple Myeloma

ArticleYear
[Correlation between Serum Free Light Chain and Blood Routine Parameters in Patients with Multiple Myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2022, Volume: 30, Issue:5

    Topics: Blood Coagulation Tests; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Retrospective Studie

2022
Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amyloid; Amyloidogenic Proteins; Amyloidosis; Blotting, Western; Ele

2017
CLINICAL, HEMATOLOGICAL CHARACTERIZATION AND POLYMORPHISM OF ABO AND Rh BLOOD GROUP SYSTEMS IN PLASMA CELL MYELOMA PATIENTS.
    Problemy radiatsiinoi medytsyny ta radiobiolohii, 2018, Volume: 23

    Topics: Aged; Alleles; beta 2-Microglobulin; Calcium; Case-Control Studies; Chernobyl Nuclear Accident; Emer

2018
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.
    Leukemia, 2013, Volume: 27, Issue:12

    Topics: Animals; Apoptosis; Cyclin-Dependent Kinases; Humans; Male; Mice; Multiple Myeloma; Phosphorylation;

2013
Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.
    Journal of gastrointestinal cancer, 2015, Volume: 46, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Benzimidazoles; Cell Proliferation; Drug Therapy, Combin

2015
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinase B; Aurora Ki

2011
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
    Blood, 2011, Nov-10, Volume: 118, Issue:19

    Topics: Apoptosis; Benzimidazoles; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; G1 Phase; Humans; Inte

2011
Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
    Pharmaceutical biology, 2012, Volume: 50, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Surviva

2012
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Drug Synergism;

2012
BENCE JONES PROTEINEMIA.
    The American journal of medicine, 1964, Volume: 37

    Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Sedimentation; Calcium; Calcium, Dietary;

1964
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: MULTIPLE MYELOMA AND LYMPHOMA.
    Cancer chemotherapy reports, 1964, Volume: 40

    Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukopenia; Lymphoma; Lymphoma, L

1964
[Two cases of Kahler's disease with azotemic evolution, without proteinuria or change in serum electrophoresis].
    Lyon medical, 1959, Sep-27, Volume: 91

    Topics: Blood Proteins; Electrophoresis; Humans; Medical Records; Multiple Myeloma; Plasma Cells; Proteinuri

1959
Homogeneous immunoglobulins in Ghanaians living in Accra, Ghana.
    African journal of medicine and medical sciences, 2004, Volume: 33, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bence Jones Protein; Blood Proteins; Calcium; Case-Contr

2004
Multiple myeloma with renal failure. A case for intensive treatment.
    Australian and New Zealand journal of medicine, 1983, Volume: 13, Issue:2

    Topics: Adult; Aged; Creatinine; Diuretics; Female; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle

1983
Long-term survival in myelomatosis. A report to the MRC working party on leukaemia in adults.
    British journal of haematology, 1982, Volume: 52, Issue:4

    Topics: Aged; Bence Jones Protein; Cyclophosphamide; Female; Hemoglobins; Humans; Immunoglobulin G; Kidney F

1982
Anaemia in patients with myelomatosis.
    British journal of cancer, 1982, Volume: 45, Issue:6

    Topics: Adult; Aged; Anemia; Blood Volume; Bone Marrow; Creatinine; Erythrocytes; Erythropoietin; Female; He

1982
Assessment of renal function in patients with multiple myeloma: the role of urinary proteins.
    Annals of hematology, 1999, Volume: 78, Issue:8

    Topics: Adult; Aged; Bence Jones Protein; Creatinine; Female; Glycoproteins; Humans; Kidney Diseases; Kidney

1999
An assessment of the clinical usefulness of plasma ribonuclease assays.
    Clinica chimica acta; international journal of clinical chemistry, 1976, Oct-15, Volume: 72, Issue:2

    Topics: Acute Kidney Injury; Breast Neoplasms; Clinical Enzyme Tests; Creatinine; Humans; Multiple Myeloma;

1976
Monitoring myelomatosis.
    Archives of internal medicine, 1975, Volume: 135, Issue:1

    Topics: Bence Jones Protein; Bone Neoplasms; Clone Cells; Hemoglobins; Humans; Immunoglobulin A; Immunoglobu

1975
Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies.
    British journal of haematology, 1992, Volume: 80, Issue:3

    Topics: Age Factors; Aged; Calcium; CD4-CD8 Ratio; Creatinine; Female; Hemoglobins; Humans; Male; Multiple M

1992
Is the newly proposed prognostic system for multiple myeloma useful?
    British journal of haematology, 1990, Volume: 75, Issue:1

    Topics: Humans; Multiple Myeloma; Prognosis; Serum Albumin; Urea

1990
A new prognostic system for multiple myeloma based on easily available parameters.
    British journal of haematology, 1989, Volume: 72, Issue:4

    Topics: Actuarial Analysis; Aged; Humans; Multiple Myeloma; Prognosis; Risk Factors; Serum Albumin; Urea

1989
The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
    British journal of cancer, 1985, Volume: 52, Issue:1

    Topics: beta 2-Microglobulin; Creatinine; Follow-Up Studies; Hemoglobins; Humans; Multiple Myeloma; Prognosi

1985
Studies on the mechanism of heat aggregation of human gamma-G.
    Journal of immunology (Baltimore, Md. : 1950), 1970, Volume: 105, Issue:4

    Topics: Bence Jones Protein; Chromatography, DEAE-Cellulose; Fucose; gamma-Globulins; Hexosamines; Hexoses;

1970
The aggregation of gamma-myeloma proteins.
    Journal of immunology (Baltimore, Md. : 1950), 1965, Volume: 95, Issue:4

    Topics: Complement System Proteins; Electrophoresis; gamma-Globulins; Hot Temperature; Humans; Immunochemist

1965
Heterogeneity of H and L chains of normal and myeloma gamma-G-globulin.
    Journal of molecular biology, 1966, Volume: 20, Issue:3

    Topics: Alkylation; Amides; Blood Protein Electrophoresis; Chromatography, Gel; gamma-Globulins; Humans; Imm

1966
Aggregation of an immunoglobulin fragment by sulfhydryl oxidation.
    Canadian journal of biochemistry, 1968, Volume: 46, Issue:8

    Topics: Acetone; Dimethylformamide; Dioxins; Fibrinolysin; Formamides; gamma-Globulins; Glycols; Guanidines;

1968
Ultracentrifugal studies of the aggregation of human immunoglobulin G by freezing and by heating.
    Acta chemica Scandinavica, 1968, Volume: 22, Issue:3

    Topics: Blood Protein Electrophoresis; Freezing; gamma-Globulins; Glycine; Hot Temperature; Humans; Multiple

1968
Equine antihapten antibody. The molecular weights of the subunits of equine immunoglobulins.
    Biochemistry, 1969, Volume: 8, Issue:3

    Topics: Alkylation; Amino Acids; Animals; Carbon Isotopes; Chromatography, Gel; Cytochromes; Detergents; gam

1969
Immunological and physicochemical studies of IgA1 (delta) cryogelglobulinaemia.
    Clinical and experimental immunology, 1973, Volume: 15, Issue:2

    Topics: Adult; Agglutinins; Anemia, Hemolytic, Autoimmune; Autoantibodies; Blood Proteins; Blood Viscosity;

1973
Chemotherapy and immunity to cancer.
    Clinical bulletin, 1974, Volume: 4, Issue:4

    Topics: Allyl Compounds; Aniline Compounds; Animals; Antineoplastic Agents; Cyclophosphamide; Fluorouracil;

1974
The kidney and intravascular coagulation in myelomatosis.
    British medical journal, 1974, Jun-08, Volume: 2, Issue:5918

    Topics: Acute Kidney Injury; Autopsy; Bence Jones Protein; Biopsy, Needle; Capillaries; Disseminated Intrava

1974
Molecular weight of a human J chain.
    Biochimica et biophysica acta, 1973, Feb-21, Volume: 295, Issue:2

    Topics: Amino Acids; Electrophoresis, Disc; Humans; Immunoglobulin A; Immunoglobulin Fragments; Immunoglobul

1973
Letter: Determinants of serum ribonuclease levels.
    The New England journal of medicine, 1974, Jul-25, Volume: 291, Issue:4

    Topics: Humans; Immunosuppression Therapy; Kidney; Multiple Myeloma; Ribonucleases; Urea

1974
Hyperviscosity syndrome in IgA multiple myeloma.
    British journal of haematology, 1974, Volume: 27, Issue:1

    Topics: Aged; Blood Coagulation Tests; Blood Proteins; Blood Transfusion; Blood Viscosity; Chylomicrons; Cyc

1974
Method of removing abnormal protein rapidly from patients with malignant paraproteinaemias.
    British medical journal, 1971, Sep-18, Volume: 3, Issue:5776

    Topics: Adult; Aged; Bicarbonates; Blood Banks; Blood Protein Disorders; Blood Viscosity; Calcium; Chlorides

1971
Chemical studies of heavy chains of two IgGl-lambda myeloma proteins from a single patient.
    Immunochemistry, 1972, Volume: 9, Issue:5

    Topics: Amino Acid Sequence; Amino Acids; Cell Differentiation; Electrophoresis, Starch Gel; Genes; Humans;

1972
An immunoglobulin light chain of subgroup III-1 of lambda type with a free sulfhydryl group.
    Canadian journal of biochemistry, 1971, Volume: 49, Issue:8

    Topics: Amino Acid Sequence; Ammonium Sulfate; Bence Jones Protein; Chemical Precipitation; Chromatography,

1971
Enzymic iodination. A probe for accessible surface proteins of normal and neoplastic lymphocytes.
    The Biochemical journal, 1971, Volume: 124, Issue:5

    Topics: Animals; Autoradiography; Cell Line; Cell Membrane; Chromatography, Gel; Electrophoresis, Disc; Hydr

1971
Factors influencing the prognosis in myelomatosis.
    Postgraduate medical journal, 1971, Volume: 47, Issue:552

    Topics: Adult; Age Factors; Aged; Anemia; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen; Pro

1971
Fragments of Bence-Jones proteins: products of degradation or of synthesis by plasmocytoma cells?
    Klinische Wochenschrift, 1970, Apr-15, Volume: 48, Issue:8

    Topics: Animals; Bence Jones Protein; Chromatography, Gel; Electrophoresis; Gels; Humans; Immune Sera; Immun

1970
[Enzymatic reoxidation of Fab fragments of completely reduced gamma globulin immunoglobulins].
    Bulletin de la Societe de chimie biologique, 1968, Sep-28, Volume: 50, Issue:5

    Topics: Animals; Centrifugation, Density Gradient; Guanidines; Humans; Immunoglobulin G; Iodine Isotopes; Mi

1968